Evidence map›Paper›PMID 37461074›Full record

ArticleOrphanet journal of rare diseases2023

Breaking down the fences among registries on autoinflammatory diseases: the E-Merge project.

Y Vyzhga, V Hentgen, R Caorsi, H Wittkowski, M Hofer, N Ruperto, E Lainka, K Theodoropoulou, D Foell, E Mosci and 2 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Y VyzhgaNational Pirogov Memorial Medical University, Vinnytsya, Ukraine. yulia_tokarchuk@yahoo.com.ORCID 0000-0002-3237-9962
V HentgenDepartment for Pediatrics, National Referral Centre of Auto-Inflammatory Diseases and Inflammatory Amyloidosis - CEREMAIA, Versailles Hospital, Le Chesnay, Paris, France.
R CaorsiCentre for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
H WittkowskiDepartment of Pediatric Rheumatology and Immunology, University Hospital Munster, Münster, Germany.
M HoferDepartment of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
N RupertoGaslini Trial Centre, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
E LainkaDepartment of Pediatric Rheumatology, University Children's Hospital Essen, Essen, Germany.
K TheodoropoulouDepartment of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
D FoellDepartment of Pediatric Rheumatology and Immunology, University Hospital Munster, Münster, Germany.
E MosciGaslini Trial Centre, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
M GattornoCentre for Autoinflammatory Diseases and Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
AID-Net, Eurofever, JIRcohort registriesthe Paediatric Rheumatology International Trials Organisation (PRINTO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong the various numbers of different autoinflammatory diseases (AIDs), the absolute majority of them remains rare, with a single representative in large populations. This project, endorsed by PRES, supported by the EMERGE fellowship program, and performed in line with the Metadata registry for the ERN RITA (MeRITA), has the objective of performing a data synchronization attempt of the most relevant research questions regarding clinical features, diagnostic strategies, and optimal management of autoinflammatory diseases.

resultsAn analysis of three large European registries: Eurofever, JIR-cohort and AID-Net, with a total coverage of 7825 patients from 278 participating centers from different countries, was performed in the context of epidemiological and clinical data merging. The data collected and evaluated in the registries does not cover only pediatric patients, but also adults with newly diagnosed AIDs. General aspects of the existing epidemiological data have been discussed in the context of patient global distribution, potential diagnostic delays, access to genetic testing, and the availability of the treatment.

conclusionsIn general, the results indicate a great potential for upcoming collaborative work using existing data in cohorts that enhance the quality of medical care performed for patients with autoinflammatory diseases.

Indexed as

Genetic TestingHereditary Autoinflammatory DiseasesAdultChildHumansRegistriesAID-NetAutoinflammatory diseasesDisease registryEurofeverJIR-cohort

Identifiers

PMID37461074
PMCPMC10353236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.